Cargando…
Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report
A 76 year-old female came to our observation one week after the vaccination with ChAdOx1 nCoV-19 AZD1222 for the onset of purpuric rash on her gluteal and legs regions associated with coxalgia and episodes of macrohaematuria. Henoch-Schönlein purpura (HSP) was diagnosed on the basis of the revised c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539285/ https://www.ncbi.nlm.nih.gov/pubmed/34696186 http://dx.doi.org/10.3390/vaccines9101078 |
_version_ | 1784588709986828288 |
---|---|
author | Sirufo, Maria Maddalena Raggiunti, Martina Magnanimi, Lina Maria Ginaldi, Lia De Martinis, Massimo |
author_facet | Sirufo, Maria Maddalena Raggiunti, Martina Magnanimi, Lina Maria Ginaldi, Lia De Martinis, Massimo |
author_sort | Sirufo, Maria Maddalena |
collection | PubMed |
description | A 76 year-old female came to our observation one week after the vaccination with ChAdOx1 nCoV-19 AZD1222 for the onset of purpuric rash on her gluteal and legs regions associated with coxalgia and episodes of macrohaematuria. Henoch-Schönlein purpura (HSP) was diagnosed on the basis of the revised criteria developed by the European League Against Rheumatism, the Paediatric Rheumatology International Trials Organization, and the Paediatric Rheumatology European Society (EULAR/PRINTO/PRES). HSP is a common IgA-mediated small vessel vasculitis, typical of childhood, that affects several systems and is characterized by a tetrad of dermatological, abdominal, joint, and renal manifestations. The Etiology of HSP is not completely understood, but it was observed following upper respiratory tract infections, medications, vaccinations, and malignancies. HSP has previously been reported following immunization with various vaccines, mostly within 12 weeks post, suggesting a possible correlation. To our knowledge, this is the first report of the possible association between COVID-19 ChAdOx1 nCoV-19 AZD1222 and the onset of HSP in a previously healthy woman. No similar cases were reported amongst 23.848 participants in the ChAdOx1 nCoV-19 AZD1222 trial. |
format | Online Article Text |
id | pubmed-8539285 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85392852021-10-24 Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report Sirufo, Maria Maddalena Raggiunti, Martina Magnanimi, Lina Maria Ginaldi, Lia De Martinis, Massimo Vaccines (Basel) Case Report A 76 year-old female came to our observation one week after the vaccination with ChAdOx1 nCoV-19 AZD1222 for the onset of purpuric rash on her gluteal and legs regions associated with coxalgia and episodes of macrohaematuria. Henoch-Schönlein purpura (HSP) was diagnosed on the basis of the revised criteria developed by the European League Against Rheumatism, the Paediatric Rheumatology International Trials Organization, and the Paediatric Rheumatology European Society (EULAR/PRINTO/PRES). HSP is a common IgA-mediated small vessel vasculitis, typical of childhood, that affects several systems and is characterized by a tetrad of dermatological, abdominal, joint, and renal manifestations. The Etiology of HSP is not completely understood, but it was observed following upper respiratory tract infections, medications, vaccinations, and malignancies. HSP has previously been reported following immunization with various vaccines, mostly within 12 weeks post, suggesting a possible correlation. To our knowledge, this is the first report of the possible association between COVID-19 ChAdOx1 nCoV-19 AZD1222 and the onset of HSP in a previously healthy woman. No similar cases were reported amongst 23.848 participants in the ChAdOx1 nCoV-19 AZD1222 trial. MDPI 2021-09-25 /pmc/articles/PMC8539285/ /pubmed/34696186 http://dx.doi.org/10.3390/vaccines9101078 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Sirufo, Maria Maddalena Raggiunti, Martina Magnanimi, Lina Maria Ginaldi, Lia De Martinis, Massimo Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report |
title | Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report |
title_full | Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report |
title_fullStr | Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report |
title_full_unstemmed | Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report |
title_short | Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report |
title_sort | henoch-schönlein purpura following the first dose of covid-19 viral vector vaccine: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539285/ https://www.ncbi.nlm.nih.gov/pubmed/34696186 http://dx.doi.org/10.3390/vaccines9101078 |
work_keys_str_mv | AT sirufomariamaddalena henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport AT raggiuntimartina henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport AT magnanimilinamaria henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport AT ginaldilia henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport AT demartinismassimo henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport |